Advisor / Senior Advisor, Cardiovascular NAMs – Investigative Toxicology
Eli Lilly and Company
August 30, 2026
On-site
Indianapolis, IN
Clinical Research and Development
Position Overview
Scientist (individual contributor) in Lilly’s NAMs/CIVMs pillar within Investigative Toxicology, primarily laboratory-based, anchoring cardiovascular safety NAM capability by crafting, qualifying, and applying human-relevant in vitro models to detect, characterize, and mechanistically understand compound-induced cardiovascular liabilities.
Key Responsibilities
- Qualify and apply cardiovascular in vitro models: hiPSC-CMs, hiPSC-ECs, 2D electrophysiological monolayers, 3D EHTs, cardiac organoids, and vessel-on-a-chip.
- Conduct mechanistic investigations into proarrhythmia/QT/AP prolongation, structural cardiomyopathy, mitochondrial cardiotoxicity, DIVI, and endothelial dysfunction/barrier disruption.
- Implement/qualify cardiac safety readouts: MEA field potential recordings, calcium flux imaging, sarcomere shortening/contractility assays, and impedance-based platforms; adopt emerging technologies aligned to CiPA and beyond.
- Use 3D platforms (EHTs/COs) for mechanistic studies and chronic dosing to capture endpoints beyond electrophysiology.
- Serve as primary scientific resource for project follow-on in vitro work.
- Collaborate with in silico ADMET Intelligence to build tiered decision frameworks.
- Evaluate emerging NAMs technologies (e.g., multi-organ liver-heart MPS, AI/ML imaging, transcriptomic profiling) and recommend adoption.
- Act as scientific point of contact for CROs/academics; coordinate study design, data quality, and deliverables.
- Stay current on regulatory/consortium developments; publish/present externally.
Minimum Requirements
- PhD in Pharmacology/Physiology/Biomed Engineering/Toxicology or related field with training in cardiac/vascular biology or cardiovascular electrophysiology.
- Advisor (R5): PhD + 2+ years postdoc/industry with hands-on advanced cardiovascular in vitro models.
- Senior Advisor (R6): PhD + 5+ years with independent contributions, model qualification, and leadership.
- Hands-on in at least one: hiPSC-CM differentiation/functional characterization; MEA-based proarrhythmia (APD/FPD) aligned to CiPA; 3D EHT functional assessment; endothelial cell/vessel-on-a-chip for DIVI/inflammation/barrier endpoints.
- Ability to independently design experiments, manage concurrent projects, and prioritize under drug discovery timelines.
Additional Skills/Preferences
- Familiarity with CiPA, ICH S7B/E14 Q&A, or FDA ISTAND NAMs pathways.
- Experience with human vascular wall microfluidic EC–smooth muscle cell bilayers under shear stress (plus).
- Strong written/oral communication (publications/presentations).
- High-content imaging, AI/ML phenotyping, or transcriptomic profiling (bulk/scRNA-seq) for mechanism-of-injury signatures.
- Cardio-oncology compound assessment (hiPSC-CM/EHT).
- Mentoring or leading project-embedded activities.
Benefits
- Eligibility for company bonus (depending on performance).
- Comprehensive benefits for eligible employees (401(k), pension, vacation, medical/dental/vision/prescription, flexible benefits, life insurance/death benefits, time off/leave, well-being benefits such as EAP and fitness).
Application Instructions
- For workplace accommodation requests when applying: complete the accommodation request form at https://careers.lilly.com/us/en/workplace-accommodation.
Scientist (individual contributor) in Lilly’s NAMs/CIVMs pillar within Investigative Toxicology, primarily laboratory-based, anchoring cardiovascular safety NAM capability by crafting, qualifying, and applying human-relevant in vitro models to detect, characterize, and mechanistically understand compound-induced cardiovascular liabilities.
Key Responsibilities
- Qualify and apply cardiovascular in vitro models: hiPSC-CMs, hiPSC-ECs, 2D electrophysiological monolayers, 3D EHTs, cardiac organoids, and vessel-on-a-chip.
- Conduct mechanistic investigations into proarrhythmia/QT/AP prolongation, structural cardiomyopathy, mitochondrial cardiotoxicity, DIVI, and endothelial dysfunction/barrier disruption.
- Implement/qualify cardiac safety readouts: MEA field potential recordings, calcium flux imaging, sarcomere shortening/contractility assays, and impedance-based platforms; adopt emerging technologies aligned to CiPA and beyond.
- Use 3D platforms (EHTs/COs) for mechanistic studies and chronic dosing to capture endpoints beyond electrophysiology.
- Serve as primary scientific resource for project follow-on in vitro work.
- Collaborate with in silico ADMET Intelligence to build tiered decision frameworks.
- Evaluate emerging NAMs technologies (e.g., multi-organ liver-heart MPS, AI/ML imaging, transcriptomic profiling) and recommend adoption.
- Act as scientific point of contact for CROs/academics; coordinate study design, data quality, and deliverables.
- Stay current on regulatory/consortium developments; publish/present externally.
Minimum Requirements
- PhD in Pharmacology/Physiology/Biomed Engineering/Toxicology or related field with training in cardiac/vascular biology or cardiovascular electrophysiology.
- Advisor (R5): PhD + 2+ years postdoc/industry with hands-on advanced cardiovascular in vitro models.
- Senior Advisor (R6): PhD + 5+ years with independent contributions, model qualification, and leadership.
- Hands-on in at least one: hiPSC-CM differentiation/functional characterization; MEA-based proarrhythmia (APD/FPD) aligned to CiPA; 3D EHT functional assessment; endothelial cell/vessel-on-a-chip for DIVI/inflammation/barrier endpoints.
- Ability to independently design experiments, manage concurrent projects, and prioritize under drug discovery timelines.
Additional Skills/Preferences
- Familiarity with CiPA, ICH S7B/E14 Q&A, or FDA ISTAND NAMs pathways.
- Experience with human vascular wall microfluidic EC–smooth muscle cell bilayers under shear stress (plus).
- Strong written/oral communication (publications/presentations).
- High-content imaging, AI/ML phenotyping, or transcriptomic profiling (bulk/scRNA-seq) for mechanism-of-injury signatures.
- Cardio-oncology compound assessment (hiPSC-CM/EHT).
- Mentoring or leading project-embedded activities.
Benefits
- Eligibility for company bonus (depending on performance).
- Comprehensive benefits for eligible employees (401(k), pension, vacation, medical/dental/vision/prescription, flexible benefits, life insurance/death benefits, time off/leave, well-being benefits such as EAP and fitness).
Application Instructions
- For workplace accommodation requests when applying: complete the accommodation request form at https://careers.lilly.com/us/en/workplace-accommodation.